stoxline Quote Chart Rank Option Currency Glossary
  
Beam Therapeutics Inc. (BEAM)
20.65  -0.29 (-1.38%)    11-17 16:00
Open: 20.825
High: 22.06
Volume: 4,125,398
  
Pre. Close: 20.94
Low: 20.5375
Market Cap: 2,137(M)
Technical analysis
2026-11-17 4:33:45 PM
Short term     
Mid term     
Targets 6-month :  30.64 1-year :  34.75
Resists First :  26.23 Second :  29.76
Pivot price 25.56
Supports First :  20.53 Second :  17.08
MAs MA(5) :  22.85 MA(20) :  25.28
MA(100) :  27.01 MA(250) :  27.81
MACD MACD :  -0.8 Signal :  -0.2
%K %D K(14,3) :  1.5 D(3) :  7.9
RSI RSI(14): 34.4
52-week High :  38.25 Low :  20.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BEAM ] has closed below the lower bollinger band by 0.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BEAM ] is to continue within current trading range. It is unclear right now based on current values. 53.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 22.09 - 22.25 22.25 - 22.37
Low: 20.15 - 20.35 20.35 - 20.51
Close: 20.37 - 20.64 20.64 - 20.85
Company Description

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Headline News

Wed, 18 Nov 2026
Need To Know: The Consensus Just Cut Its Beam Therapeutics Inc. (NASDAQ:BEAM) Estimates For 2027 - Simply Wall St

Tue, 03 Nov 2026
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Wed, 30 Sep 2026
Beam Therapeutics sues base editing rival, claims former scientist stole secrets - Fierce Biotech

Tue, 29 Sep 2026
Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property - STAT

Wed, 16 Sep 2026
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire

Tue, 08 Sep 2026
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 104 (M)
Held by Insiders 8.807e+007 (%)
Held by Institutions 1.2 (%)
Shares Short 25,880 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.7041e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -73.9 %
Operating Margin -46 %
Return on Assets (ttm) 33.2 %
Return on Equity (ttm) -19.1 %
Qtrly Rev. Growth 1.4664e+008 %
Gross Profit (p.s.) -43.61
Sales Per Share -5.09
EBITDA (p.s.) -1.1818e+008
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -389 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -4.07
Price to Cash Flow 4.79
Stock Dividends
Dividend 0
Forward Dividend 2.624e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android